Melissa Angell of Law360 has this coverage of our qui tam case against Allergan: A California federal judge rejected Allergan's bid to dodge a False Claims Act lawsuit Friday, finding the patent attorney behind the suit sufficiently alleged that the pharmaceutical company fraudulently obtained two dementia drug patents to allegedly monopolize pricing and out-compete generics…

Bloomberg Law has this coverage of our qui tam cases against Allergan, Janssen, and Valeant: Drug companies that allegedly defrauded the government to extend monopolies on brand name drugs face novel legal challenges under the False Claims Act from a patent lawyer who says the cases are a new front in the battle over pricey medications …

Politico has this coverage of Herrera Purdy's Apriso qui tam suit: FALSE CLAIMS SUITS POSE NEW PATENT CHALLENGE PATHWAY — An argument heard in San Francisco Federal District Court earlier this month — and teed up in a similar case in October — could open a new door...

Bloomberg Law has this coverage of our Zytiga qui tam case: A patent attorney is using the False Claims Act to sue brand-name drug companies over extending their patent protections, potentially carving a new legal path for stopping big-brand drugmakers …